Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

CIPLA's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 0.00000
forwardPE 22.67804
debtToEquity 1.40400
earningsGrowth 0.10200
revenueGrowth 0.03200
grossMargins 0.66691
operatingMargins 0.22311
trailingEps 66.74000
forwardEps 63.54000

CIPLA's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
CIPLA's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
Cipla Limited's forward EPS being less than trailing EPS suggests the company may see a drop in profitability this year. This signals potential financial challenges and a less optimistic outlook for earnings growth.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

Price projections for CIPLA have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in CIPLA's future potential and financial outlook among analysts.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


CIPLA had 2 sell transactions, while the market price was at 1590.4249877929688 per share.Throughout the period under consideration, there were no sell transactions.An increase in buying activity relative to selling at Cipla Limited's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


Analysts' buy bias toward CIPLA suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, CIPLA is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.